anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the technical field of treating tumor by immunization therapy, in particular to a method for treating intestinal cancer and pancreatic cancer cells by methionine enkephalin under conditions of in-vivo injection and in-vitro cell culture so as to achieve the treating aim. The methionine enkephalin is prepared into injection according to 0.0001 to 10 milligram/milliliter or carries out stimulus under the condition of cell culture of in-vitro T lymphocyte. After the concentration range of the methionine enkephalin is between 10<-2> and 10<-16> gram molecule/liter, the methionine enkephalin is fed back to internal, or is directly injected through vein, hypodermic and muscle. The method is characterized in that the methionine enkephalin directly acts on immune system cells or cancer cells in-vivo or in-vitro under culture condition with small dosage and high efficiency. The immune system cells activated by the methionine enkephalin have higher efficient of immunological cell proliferation number and cytoactive than those activated by the prior method, generally 5 to 10 times higher than the prior method, particularly the number of the T lymphocyte is significantly increased. The methionine enkephalin directly kills intestinal cancer and pancreatic cancer cells through receptor binding.
This invention relates to dentistry, and more particularly to cosmetic dentistry, where for aesthetic objectives it is desirable to remove a small amount of the patient's tooth enamel to modify tooth color. A procedure is described using an applicator and compound which provides accelerated treatment time in stripping away a sufficient amount of the outer layer of the tooth enamel to provide the necessary tooth color modification. The applicator has two functional ends. One end has a containment pocket for holding the compound, and a second end for high pressure scouring of the tooth enamel. The compound comprises an enamel softening acid, such as hydrochloric acid, in the concentration range of between 6%-16% in combination with an abrasive particulate material. The abrasive material should have a hardness greater than 6.0 as measured on the Mohs hardness scale for greatest effectiveness.
A composite of foamed substance and soap substance includes a foamed substance formed according to a selected shape and encased by a soap substance. When the soap substance is almost totally consumed, it can still attach to the foamed substance so that it can be fully used. After the soap substance is exhausted, the foamed substance can still be used continuously. The foamed substance has a fiber structure which can be rubbed to easily generate a greater amount of fine foams to save consumption of the soap substance and achieve a cleaning effect. The foamed substance is formed by interweaving of foamed substance fibers which have a surface covered by a resin layer. The resin layer is elastic and can enhance the extensibility of the foamed substance, and can also be permeated with a water-base pigment to enhance the aesthetic and visual appealing of the entire product.
PURPOSE:To obtain a percutaneous absorption promoter capable of promoting percutaneous absorption of a medicinal component in a dermal agent for external use in both a closed system and an open system and excellent in safety and stability. CONSTITUTION:A percutaneous absorption promoter composed of hydrogenated bisabol represented by the formula. The compound of the formula can be synthesized by hydrogenating natural alpha-bisabol. If 0.01 to 10wt.% compound of the formula is added to a dermal agent composition for external use containing a bioactive substance, a dermal agent composition for external use improved in the amount of the dermal medicinal component absorbed into the lower cutaneous tissue and in the amount of the systemically active component transferred into the systemic blood flow is prepared. In this composition, one of 5 to 60wt.% ethanol, 2 to 20wt.% water-soluble polyvalent alcohol (e.g. propylene glycol or glycerin), 0.01 to 2wt.% water-soluble polymer (e.g. PVA, xanthan gum or CMC) and 0.1 to 10wt.% nonionic surfactant (e.g. a polyoxyethylene sorbitan fatty acid ester) may be blended.
The invention relates to an insulinotropic peptide from human blood, in particular GCAP-II-(89-112) (guanylate-cyclase C-activating peptide II) whose structure has been determined with a view to diagnostic, medical and industrial applications as a drug. An analog GCAP-I-(99-115) isolated from urine is also claimed. The molecular shape of GCAP-II-(89-112) was determined by sequence analysis and mass spectrometry. Different biological activity and differences in the spatial peptide structure of GCAP-II-(89-112) compared to other GCAP-II-(89-112) fragments show that this GCAP-II-fragment is a natural peptide of the same family as the claimed peptide group whose members can be used in the treatment of many disorders associated with disturbances in glucose or electrolyte transport and insulin secretion in cells, and specifically in the treatment of endocrine disorders. The operating principle of, for example, GCAP-II-(89-112) in the context of insulin secretion by the endocrine pancreas and thus of secretion of other analog substances was thus determined and can be used to develop potent anti-diabetic drugs. In addition, GCAP-I-(99-115) and GCAP-II-(89-112) (guanylate-cyclase C-activating peptides I and II) can be used in pure form or as a natural raw extract for industrial purposes in investigating new cell functions. Knowledge obtained on the cDNA and gene structure of GCAP-II-(89-112) and GCAP-I-(99-115) can be of significance for diagnostic and therapeutic ends.
Initially, the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
Ropivacain Fresenius 0.2% is a solution for infusion/ injection and will be continuously administered with an elastomer pump through the surgically placed intercostal catheter (ICC) between parietal pleura and fascia endo-thoracica at the level of surgical incision for a maximum of 72 hours at an initial standard flow rate setting of 6 ml/h using 2 mg/ml ropivacaine. In case pain exceeds 7 on NRS later than 2 hours after skin closure the flow rate will be adjusted on 8 ml/h. Furthermore, Ropivacain Fresenius 0.2% will be provided in a 20 ml glass vial for flushing the infusion line and subpleural administration.
This study aims to provide an overview on contemporary open surgical approaches for the management of carotid artery stenosis. A comprehensive literature search was performed to identify and categorize open surgery intervention techniques for the management of carotid artery stenosis, focusing on the benefits and drawbacks of each technique. Five surgical techniques for carotid endarterectomy (CEA) have been described: CEA with primary closure, CEA with patch closure, CEA by eversion technique, CEA by modified eversion technique and CEA by partial eversion. Evidence has reported significantly higher rates of perioperative complications after CEA with primary closure, including 30-days stroke rate and late restenosis. Although more recent techniques have been reported to provide superior outcomes, electing the best surgical technique is still a matter of debate. Also, CEA using a mini-skin incision has been associated to lower risk of cranial/cervical nerve injury and shorter length of hospital stay. The selection of the surgical intervention should be tailored and have into consideration individual patient characteristics, clinical considerations, surgeon preference and surgical team expertise. Further large-scale randomized clinical trials are needed to support more robust decisions on the choice of contemporary open surgical approaches to manage carotid stenosis.
FIELD: biotechnology, molecular biology, polypeptides, pharmacy. SUBSTANCE: invention represents polypeptide able to formation of antigen-binding structures exhibiting specificity to rhesus-D-antigens. The prepared polypeptide being as Fab-fragment can be used directly in pharmaceutical and diagnostic compositions as an active component. Fab-fragment and DNA sequence for its encoding can be used for preparing complete recombinant anti-rhesus-D-antibodies useful in pharmaceutical and diagnostic compositions. EFFECT: improved preparing method, valuable biological properties of polypeptide. 20 cl, 10 tbl, 35 dwg
The present invention relates to a skin-whitening function of a kojic acid derivative coupled with a peptide. More specifically, the present invention relates to a skin-whitening composition including a kojic acid derivative produced by introducing a peptide to kojic acid as an active ingredient; a method for producing a nano-liposome having an encapsulated kojic acid derivative coupled with a peptide; and a nano-liposome produced through the same. The kojic acid derivative coupled with a peptide according to the present invention has low skin irritation and has excellent activities in inhibiting tyrosinase and controlling the generation of melanin. A composition including the kojic acid derivative coupled with a peptide according to the present invention as an active ingredient can be useful in the medical product and cosmetic product industries as a functional material for whitening skin. Also, the method of the present invention has an excellent collecting rate even after a long time because a kojic acid derivative coupled with a peptide which is a whitening activating component is stably encapsulated in a nano-liposome. The kojic acid derivative-encapsulating nano-liposome produced through the method of the present invention can resolve problems, such as precipitate generation, discoloration, and smell change of a whitening activating component (a kojic acid derivative coupled with a peptide) caused by elapsed time, through formulation stability.
The invention provides PD-L1-loaded antibody bionic targeting TiO 2 Nanoparticles, a preparation method and application thereof, belonging to the field of biomedical materials. The TiO being 2 The nanoparticle is bionic TiO carrying programmed cell death receptor-ligand 1 antibody 2 Nanoparticles; the bionic TiO 2 The nano-particle is made of TiO 2 Nanoparticles, DSPE-PEG2000-NH 2 And cell membrane as raw materials; TiO2 2 Nanoparticles, DSPE-PEG2000-NH 2 And the mass ratio of the cell membrane to the cell membrane is (1-5): (1-5): (1-5). The particle diameter of the nanoparticlesSmall, high antibody carrying rate and no obvious cytotoxicity. Meanwhile, the nanoparticle can be well homologously targeted and specifically targeted to combine with malignant melanoma cells, so that apoptosis is caused. In addition, the nano-particles have biological safety, have relatively strong targeted aggregation capability after intratumoral injection, and can better inhibit the growth of malignant melanoma under the SDT condition. Can be used for treating tumors, particularly malignant melanoma, and has good application prospect.
INTRODUCTION: Opioid analgesics are often used to manage moderate to severe pain. A significant proportion of patients taking opioids have compromised kidney function. This systematic review aimed to examine the available evidence on the safety and analgesic effect of opioid use in adults with kidney disease.
METHODS: We searched eight electronic databases from inception to January 26, 2023. Published original research articles in English reporting on opioid use and pharmacokinetic data among adults with reduced renal function were included. Article screening, data extraction, and quality assessment were conducted by at least two investigators independently. This review was registered prospectively on PROSPERO (ID: CRD42020159091).
RESULTS: There were 32 observational studies included, 14 of which reported on morphine use, three involved fentanyl use, two involved hydromorphone use, and 13 articles reported on other opioids including codeine, dihydrocodeine, and buprenorphine.
CONCLUSION: There is limited and low-quality evidence to inform the safety and analgesic effect of opioid use in reduced renal function. Morphine remains the opioid for which there is the most evidence available on safety and analgesic effect in the context of renal disease. Greater caution and consideration of potential risks and benefits should be applied when using other opioids. Further high-quality studies examining clinical outcomes associated with the use of different opioids and opioid doses in renal disease are warranted.
PURPOSE: Patients with cancer may experience pain from cancer itself or its treatment. Additionally, chronic pain (CP) predating a patient's cancer diagnosis may make the etiology of pain less clear and the management of pain more complex. In this brief report, we investigated differences in biopsychosocial characteristics, pain severity, and opioid consumption, comparing groups of cancer patients with and without a history of CP who presented to the emergency department (ED) with a complaint of cancer-related pain.
METHODS: This secondary analysis of a prospective cohort study included patients with cancer who presented to the ED with a complaint of pain (≥ 4/10). Sociodemographic, clinical, psychological, and pain characteristics were assessed in the ED and subsequent hospitalization. Mann-Whitney U-, T-, and Chi-square tests were used to compare differences between patients with and without pre-existing CP before cancer.
RESULTS: Patients with pre-existing CP had lower income (p = 0.21) and less formal education (p = 0.25) and were more likely to have a diagnosis of depression or substance use disorder (p < 0.01). Patients with pre-existing CP reported significantly greater pain severity in the ED and during hospitalization compared to those without pre-existing CP (p < 0.05), despite receiving greater amounts of opioid analgesics (p = 0.036).
CONCLUSION: Identifying a history of pre-existing CP during intake may help identify patients with cancer with difficult to manage pain, who may particularly benefit from multimodal interventions and supportive care. In addition, referral of these patients for the management of co-occurring pain disorders may help decrease the usage of the ED for undertreated pain.
Steroid-induced osteonecrosis of the femoral head (SONFH) is a debilitating condition caused by long-term corticosteroid use, leading to impaired blood flow and bone cell death. The disruption of cellular processes and promotion of apoptosis by endoplasmic reticulum stress (ERS) is implicated in the pathogenesis of SONFH. We identified ERS-associated genes in SONFH and investigated their potential as therapeutic targets. We analysed the GSE123568 GEO dataset to identify differentially expressed genes (DEGs) related to ERS in SONFH. We conducted Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, identified hub genes by protein-protein interaction (PPI) analyses, and evaluated their functions by gene set enrichment analysis (GSEA). We constructed mRNA-miRNA networks, identified potential therapeutics, and assessed immune cell infiltration. We performed cross-validation using the GEO dataset GSE74089, qRT-PCR on clinical samples from patients with SONFH and controls, and a receiver operating characteristic (ROC) curve analysis to assess the diagnostic performance of the hub genes. We identified 195 ERS-related genes in SONFH, which were primarily involved in oxidative stress, immune responses, and metabolic pathways. The PPI network suggested CXCL8, STAT3, IL1B, TLR4, PTGS2, TLR2, CASP1, CYBB, CAT, and HOMX1 to be key hub genes, which were shown by GSEA to be involved in biological pathways related to metabolism, immune modulation, and cellular integrity. We also identified 261 microRNAs (miRNAs) as well as drugs such as dibenziodolium and N-acetyl-L-cysteine that modulated inflammatory responses in SONFH. Twenty-two immune cell subtypes showed significant correlations, such as a positive correlation between activated mast cells and Tregs, and patients with SONFH had fewer dendritic cells than controls. The hub genes CYBB and TLR4 showed significant correlations with M1 macrophages and CD8 T cells, respectively. Cross-validation and qRT-PCR confirmed the upregulation of STAT3, IL1B, TLR2, and CASP1 in patients with SONFH, validating the bioinformatics findings. An ROC curve analysis confirmed the diagnostic potential of the hub genes. The top 10 hub genes show promise as ERS-related diagnostic biomarkers for SONFH. We discovered that 261 miRNAs, including hsa-miR-23, influence these genes and identified potential therapeutics such as dibenziodolium and simvastatin. Immune profiling indicated altered immune functions in SONFH, with significant correlations among immune cell types. Validation confirmed the upregulation of STAT3, IL1B, TLR2 and CASP1, which had diagnostic potential. The findings suggest potential diagnostic markers and therapeutic targets for SONFH.
Methods and compositions for promoting sleep in an animal are provided. In a general aspect, a sleep promoting amount of astaxanthin and a sleep promoting amount of melatonin are administered in conjunction to an animal. The astaxanthin can be administered in an amount ranging from about 0.1 to about 60 mg/kg/body weight of the animal. The melatonin can be administered in an amount ranging from about U. I to about 40 mg/kg/body weight of the animal. The method can further comprise administering in conjunction a sleep promoting amount of zinc to the animal. The zinc can be administered in an amount ranging from about 10 to about 100 mg/kg/body weight of the animal.
Obesity is a worldwide pandemic and major risk factor for the development of metabolic syndrome (MetS) and type 2 diabetes (T2D). T2D requires lifelong medical support to limit complications and is defined by impaired glucose tolerance, insulin resistance (IR), and chronic low-level systemic inflammation initiating from adipose tissue. The current preventative strategies include a healthy diet, controlled physical activity, and medication targeting hyperglycemia, with underexplored underlying inflammation. Studies suggest a protective role for helminth infection in the prevention of T2D. The mechanisms may involve induction of modified type 2 and regulatory immune responses that suppress inflammation and promote insulin sensitivity. In this review, the roles of helminths in counteracting MetS, and prospects for harnessing these protective mechanisms for the development of novel anti-diabetes drugs are discussed.
Computer-implemented methods, systems and devices having segmented numeral character recognition. In an embodiment, users may take digital pictures of a seven-segment display on a sensor device. For example, a user at a remote location may use a digital camera to capture a digital image of a seven-segment display on a sensor device. Captured images of a seven-segment display may then be sent or uploaded over a network to a remote health management system. The health care management system includes a reader that processes the received images to determine sensor readings representative of the values output on the seven-segment displays of the remote sensor devices. Machine learning and OCR are used to identify numeric characters in images associated with seven-segment displays. In this way, a remote heath management system can obtain sensor readings from remote locations when users only have access to sensor devices with seven-segment displays.
A good bowel preparation regime is one that is not only effective in cleansing the colon but should be relatively small in volume and well-tolerated by patients with minimal adverse gastrointestinal symptoms. At our centre, reduced-volume 2-litre PEG-ELS plus bisacodyl and low fiber diet is used for bowel preparation for patients undergoing colonoscopy. Patients undergoing morning outpatient colonoscopy would normally ingest the PEG-ELS and bisacodyl the day before. This regime has been shown to be better tolerated by patients without compromising the quality of bowel preparation when compared with conventional 4-liter PEG-ELS. However, previous study on patient satisfaction found that nearly half of the patients attending the outpatient colonoscopy service at our centre were dissatisfied with the bowel preparation regime used. Of the seven items considered in the evaluation of patient satisfaction, comfort level during bowel preparation was the main cause of unfavorable responses. Moreover, a separate study using the same bowel preparation regime at our centre found a high percentage of poor quality bowel preparation, which was associated with increased technical difficulty and patient discomfort during colonoscopy. There was clearly a need for a better bowel preparation regime. Current literature suggests that either taking reduced-volume PEG-ELS on the same morning instead of the previous evening, or splitting the bowel preparation, would be better. However, whether the former or the latter is better, is unknown. The aim of our study was to compare the use of same-morning whole-dose reduced-volume PEG-ELS and split-dose reduced-volume PEG-ELS for bowel preparation for patients undergoing morning outpatient colonoscopy.
Teratogenic effects. Pregnancy Category C.

Retinoids may cause fetal harm, when administered to pregnant women. Adapalene has been shown to be teratogenic in rats and rabbits when administered orally (see Animal Data below). There are no adequate and well-controlled studies in pregnant women. Adapalene gel, 0.3% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The safety and efficacy of adapalene gel, 0.3% in pregnancy has not been established.

Human Data

In clinical trials involving adapalene gel, 0.3% in the treatment of acne vulgaris, women of child-bearing potential initiated treatment only after having had a negative pregnancy test and used effective birth control measures during therapy. However, 6 women treated with adapalene gel, 0.3% became pregnant. One patient elected to terminate the pregnancy, two patients delivered healthy babies by normal delivery, two patients delivered prematurely and the babies remained in intensive care until reaching a healthy state and one patient was lost to follow-up.

Animal Data

  * No teratogenic effects were seen in rats at oral doses of 0.15 to 5.0 mg/kg/day adapalene representing up to 6 times the maximum recommended human dose (MRHD) based on mg/m2comparisons. Adapalene has been shown to be teratogenic in rats and rabbits when administered orally at doses ≥ 25 mg/kg representing 32 and 65 times, respectively, the MRHD based on mg/m2comparisons. Findings included cleft palate, microphthalmia, encephalocele and skeletal abnormalities in the rat and umbilical hernia, exophthalmos and kidney and skeletal abnormalities in the rabbit.
  * Cutaneous teratology studies in rats and rabbits at doses of 0.6, 2.0, and 6.0 mg/kg/day exhibited no fetotoxicity and only minimal increases in supernumerary ribs in both species and delayed ossification in rabbits. Systemic exposure (AUC0 to 24h) to adapalene 0.3% gel at topical doses of 6.0 mg/kg/day in rats and rabbits represented 5.7 and 28.7 times, respectively, the exposure in acne patients treated with adapalene 0.3% gel applied to the face, chest and back (2 grams applied to 1000 cm2of acne involved skin).
Timing and type of resection will be established by the treating physician. Follow up strategy after surgery consists of imaging studies (MR or CT), every 6 months for the first two years and yearly thereafter for five years. An high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making. Date of surgery does not change the timing of follow up which starts from the date of enrolment.